首页> 美国卫生研究院文献>Frontiers in Pharmacology >Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
【2h】

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

机译:氯胺酮的抗抑郁作用:速效新型抗抑郁药的潜在机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Newer antidepressants are needed for the many individuals with major depressive disorder (MDD) that do not respond adequately to treatment and because of a delay of weeks before the emergence of therapeutic effects. Recent evidence from clinical trials shows that the NMDA antagonist ketamine is a revolutionary novel antidepressant because it acts rapidly and is effective for treatment-resistant patients. A single infusion of ketamine alleviates depressive symptoms in treatment-resistant depressed patients within hours and these effects may be sustained for up to 2 weeks. Although the discovery of ketamine's effects has reshaped drug discovery for antidepressants, the psychotomimetic properties of this compound limit the use of this therapy to the most severely ill patients. In order to develop additional antidepressants like ketamine, adequate preclinical behavioral screening paradigms for fast-acting antidepressants need to be established and used to identify the underlying neural mechanisms. This review examines the preclinical literature attempting to model the antidepressant-like effects of ketamine. Acute administration of ketamine has produced effects in behavioral screens for antidepressants like the forced swim test, novelty suppression of feeding and in rodent models for depression. Protracted behavioral effects of ketamine have been reported to appear after a single treatment that last for days. This temporal pattern is similar to its clinical effects and may serve as a new animal paradigm for rapid antidepressant effects in humans. In addition, protracted changes in molecules mediating synaptic plasticity have been implicated in mediating the antidepressant-like behavioral effects of ketamine. Current preclinical studies are examining compounds with more specific pharmacological effects at glutamate receptors and synapses in order to develop additional rapidly acting antidepressants without the hallucinogenic side effects or abuse potential of ketamine.
机译:对于许多重度抑郁症(MDD)个体,由于对治疗效果的延迟需要数周时间,因此他们对治疗没有足够的反应,因此需要更新的抗抑郁药。来自临床试验的最新证据表明,NMDA拮抗剂氯胺酮是一种革命性的新型抗抑郁药,因为它作用迅速且对耐药患者有效。氯胺酮的单次输注可在数小时内缓解耐治疗的抑郁症患者的抑郁症状,这些作用可能持续长达2周。尽管氯胺酮作用的发现已重塑了抗抑郁药的药物发现,但该化合物的拟精神特性将这种疗法的使用限制于重症患者。为了开发其他抗抑郁药(如氯胺酮),需要为速效抗抑郁药建立足够的临床前行为筛查范例,并将其用于识别潜在的神经机制。这篇综述检查了试图模拟氯胺酮类抗抑郁药作用的临床前文献。氯胺酮的急性给药已在抗抑郁药的行为筛选中产生了作用,如强迫游泳试验,抑制进食的新颖性以及在啮齿类动物的抑郁症模型中。氯胺酮的持续行为影响据报道在持续数天的单次治疗后出现。这种时间模式与其临床效果相似,并且可以作为人类快速抗抑郁作用的新动物范例。另外,介导突触可塑性的分子的长期变化已被牵涉到介导氯胺酮的抗抑郁样行为作用。当前的临床前研究正在研究对谷氨酸受体和突触具有更具体药理作用的化合物,以开发出更多的速效抗抑郁药,而不会产生致幻剂副作用或氯胺酮的滥用潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号